Best Time to Take Iron
Read More
Can Cagrilintide Cause Low Libido?
Key Takeaways
Current clinical trial data does not list low libido as a confirmed side effect of cagrilintide, so no direct causal link has been established.
Rapid weight loss itself, not the drug, is the more likely explanation for libido changes, as caloric restriction alters sex hormone levels.
Common side effects like nausea and fatigue can reduce interest in sexual activity through general physical discomfort rather than hormonal interference.
Hormone shifts during active weight loss are often temporary and may actually improve long-term as weight stabilizes and metabolic health recovers.
Libido changes lasting more than 4 to 6 weeks on a stable dose should prompt a clinical evaluation, including a full hormone panel, before considering stopping the medication.
What Cagrilintide Is and How It Works
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, currently being evaluated in phase 3 trials both as a standalone therapy and in combination with semaglutide under the name CagriSema. It works by mimicking amylin, a hormone naturally released from the pancreas that slows gastric emptying, reduces appetite, and signals fullness to the brain.
Unlike GLP-1 receptor agonists such as semaglutide or tirzepatide, cagrilintide targets amylin and calcitonin receptors. This gives it a distinct mechanism that affects appetite regulation through a different pathway, which is part of why researchers believe combining it with a GLP-1 drug may produce stronger weight loss results. Understanding this mechanism is important when evaluating whether the drug itself could directly affect libido, or whether other factors are more likely at play.
What the Clinical Trial Data Actually Shows
The short answer is that low libido is not listed as a documented adverse event in cagrilintide's published safety profiles, including data from the ongoing REDEFINE clinical trial program. No peer-reviewed literature as of early 2025 has established a direct causal link between cagrilintide and reduced sexual desire.
However, this does not mean the concern is unfounded. Sexual dysfunction is rarely a primary endpoint in metabolic drug trials, which means it may be underreported rather than truly absent. Patients in trials are more likely to report nausea, vomiting, or injection site reactions because those are the outcomes researchers are tracking most closely. Libido changes, which can feel personal or difficult to raise with study coordinators, may not make it into published safety summaries even when they occur.
For now, the honest scientific position is that there is no confirmed direct link, but the data available does not fully rule out the possibility either.
How Weight Loss Itself Can Affect Sex Drive
This is where the more likely explanation lives for most patients. Rapid caloric restriction and significant weight loss alter the balance of sex hormones in ways that can suppress libido regardless of which medication is being used.
Fat tissue is a major site of estrogen production and conversion in the body. Losing body fat quickly can shift circulating estrogen levels, which affects both men and women. In men, aggressive weight loss can temporarily lower free testosterone even as overall metabolic health improves. Caloric deficits during active weight loss phases are also associated with temporary suppression of the HPA axis, the hormonal system that regulates stress responses and reproductive hormones.
On top of hormonal changes, the common side effects of cagrilintide, including nausea, fatigue, and gastrointestinal discomfort, can simply reduce interest in sexual activity through general physical discomfort. Feeling unwell day to day is not a direct pharmacological effect on libido, but it produces a very similar outcome.
The important nuance here is that sustained weight loss over time often improves libido in the long run. Better cardiovascular function, improved insulin sensitivity, and more positive body image are all associated with increased sexual desire after weight stabilizes.
Comparing Cagrilintide to Similar Weight Loss Medications
Putting cagrilintide in context alongside other commonly used weight loss drugs helps clarify whether this is a unique concern or a broader pattern.
Medication |
Mechanism of Action |
Documented Sexual Side Effects |
Indirect Libido Risk Factors |
|---|---|---|---|
Cagrilintide |
Amylin and calcitonin receptor agonist |
None confirmed in current data |
Caloric restriction, nausea, fatigue |
Semaglutide (Ozempic, Wegovy) |
GLP-1 receptor agonist |
None directly established |
Caloric restriction, GI side effects |
Tirzepatide (Mounjaro, Zepbound) |
Dual GIP and GLP-1 receptor agonist |
None directly established |
Caloric restriction, GI side effects |
Older weight loss medications such as phentermine carry stronger evidence of direct effects on sexual function through sympathomimetic mechanisms. Cagrilintide's amylin-based mechanism does not directly modulate sex hormone pathways based on current understanding, which puts it closer to the GLP-1 class in terms of indirect rather than direct libido risk.
The Hormone Connection: What to Watch For
If you are noticing changes in sexual desire while on cagrilintide or any weight loss medication, the most useful first step is understanding which hormones to evaluate. A full panel including total testosterone, free testosterone, estradiol, and thyroid function can help rule out causes unrelated to the drug or weight loss process.
Mental health factors are also frequently overlooked contributors. Depression, anxiety, and body image concerns are common during active weight loss periods and can meaningfully reduce libido without any hormonal component. Patients who are working hard to change their bodies sometimes experience unexpected emotional complexity around that process, and those feelings deserve attention alongside physical assessments.
It is also worth noting that libido naturally fluctuates based on sleep, stress, relationship dynamics, and life circumstances. Attributing every change in sex drive to a new medication may lead to unnecessary alarm or premature discontinuation of a treatment that could be beneficial overall.
When to Bring This Up With a Clinician
Libido changes lasting more than 4 to 6 weeks on a stable dose of cagrilintide are worth discussing with a healthcare provider. That timeline matters because early side effects like nausea and fatigue tend to improve as the body adjusts, and any associated libido suppression may resolve along with them.
Do not stop taking cagrilintide based on libido changes alone without clinical guidance. The potential benefits of the medication for metabolic health, weight management, and long-term cardiovascular risk may outweigh temporary sexual side effects, particularly if the underlying cause can be identified and addressed. A clinician can evaluate your hormone levels, assess your mental health, and help you weigh the full picture before recommending any change to your treatment plan.
With Doctronic's 22 million-plus AI consultations and 99.2% treatment plan alignment with board-certified physicians, patients now have a fast, accessible option to get a real clinical assessment of concerns like these without waiting weeks for a traditional appointment.
Frequently Asked Questions
No. As of early 2025, low libido is not listed as a documented adverse event in cagrilintide's published clinical trial safety profiles, including data from the REDEFINE program. However, sexual dysfunction is rarely a primary endpoint in metabolic drug trials, which means it may be underreported rather than truly absent from patient experiences.
Yes, and this is likely the more common explanation. Significant caloric restriction can suppress the HPA axis and shift circulating levels of testosterone and estrogen. These hormonal changes can temporarily reduce libido independent of any medication. As weight stabilizes and metabolic health improves, sex drive often recovers on its own over time.
No direct testosterone suppression from CagriSema has been documented in current clinical data. Any testosterone changes observed during treatment are more likely linked to rapid fat loss, since fat tissue plays a role in hormone production and conversion. A clinician can order a hormone panel to assess your individual levels if you have concerns.
Duration varies by individual. Libido changes tied to caloric restriction and GI side effects often improve as the body adapts to a stable lower dose or as weight loss slows. Changes lasting more than 4 to 6 weeks on a stable dose suggest a deeper evaluation is needed to rule out hormonal, psychological, or unrelated medical causes.
No, you should not stop on your own without consulting a clinician first. A drop in libido has multiple possible causes, many unrelated to the medication itself. A healthcare provider can assess your hormone levels, mental health, and overall response to treatment before recommending any change to your medication plan.
The Bottom Line
Cagrilintide is not established as a direct cause of low libido based on current clinical evidence. The more likely explanation for any sexual side effects patients notice is the indirect impact of rapid weight loss on hormone levels, combined with common side effects like nausea and fatigue. Hormone shifts during active weight loss are often temporary, and libido frequently improves as weight stabilizes and cardiovascular and metabolic health recover. That said, if you are experiencing persistent changes in sexual desire, getting a real clinical assessment matters. Doctronic, the first AI legally authorized to practice medicine, offers free AI consultations and $39 video visits available 24/7, so you can get answers fast without waiting weeks for a traditional appointment. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
